Kissei Pharmaceutical Co Ltd


Latest Trade




Today's Range




52 Week Range




As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Kissei Pharmaceutical says marketing approval for "Beova® Tablets 50mg" for treatment of overactive bladder

Sept 21(Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Kissei Pharmaceutical Co Ltd and KYORIN Holdings, Inc. <<<4569.T>>> jointly announced today that KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., received approval from the Ministry of Health, Labour and Welfare as of September 21, 2018 to market 'Beova® Tablets 50mg' for the treatment of overactive bladder.

Kissei Pharmaceutical says change of president

April 23 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it appoints Yoshio Furihata as president, to succeed Masaki Morozumi, effective June 27 .

Kissei Pharmaceutical says rating withdrawal by R&I

April 13 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says Rating and Investment Information, Inc. (R&I) withdrew the rating on the company of "A-" -R&I.

Kissei Pharmaceutical completes share repurchase

Feb 13 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it completed repurchase of 1.6 million shares of its common stock, for 4.46 billion yen in total, through ToSTNeT-3, on Feb. 13 .

Kissei Pharmaceutical to repurchase up to 3.7 pct shares and retire treasury shares

Feb 9 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it will repurchase up to 1.8 million shares, representing 3.7 percent of outstanding, for up to 5.02 billion yen, through ToSTNeT-3, on Feb. 13 .Says it will retire 2.5 million shares (4.6 percent of outstanding) of its common stock on March 9 .

JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study

Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .

Vifor Pharma: Kissei to market avacopan in Japan


R&I affirms Kissei Pharmaceutical's rating at "A-" and says stable outlook – R&I

Kissei Pharmaceutical Co Ltd <4547.T>: Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" – R&I .Rating outlook stable– R&I.

Kyorin and KISSEI sign agreement for co-development and co-marketing of KRP-114V

Kyorin Holdings Inc:KYORIN Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc. and Kissei Pharmaceutical Co., Ltd. jointly announced a co-development and co-marketing agreement for an overactive bladder medication of KRP-114V (INN: Vibegron) which is being developed by Kyorin in Japan.

KISSEI PHARMACEUTICAL to retire treasury shares

KISSEI PHARMACEUTICAL CO LTD:To retire 2,600,000 shares (4.57 pct stake) of its common stock on May 15.Says the total shares outstanding will be 54,311,185 shares after the retirement.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.